Under the auspices of The Bates College Merck Fellowhsip Program in Biology and Chemistry, Merck will discuss The Invention and Development of CRIXIVAN: An HIV Protease Inhibitor at 4 p.m. in Room 204 of Carnegie Science Hall. He will deliver his second lecture of the day, AIDS Therapy: The Power of Combination Treatments, at 7 p.m. in Chase Hall Lounge. Geared more toward a general audience, this second talk will address the increased effectiveness of anti-HIV and anti-AIDS drugs when used together.

Dorsey is part of the Merck research team that developed CRIXIVAN, an effective drug in the protease inhibitor class used to combat HIV, the virus that causes AIDS.